功能失调高密度脂蛋白中的对称二甲基精氨酸介导慢性肾脏病内皮糖萼破坏
这项转化性横断面研究探讨了功能失调高密度脂蛋白(d-HDL)中对称二甲基精氨酸(SDMA)是否介导内皮糖萼损伤。体外实验显示透析患者HDL及外源性SDMA呈剂量依赖性破坏内皮细胞糖萼,经TLR2和MMP-9通路;活体显微镜证实SDMA和d-HDL导致糖萼分解及白细胞滚动改变。生物有效HDL是唯一可独立预测体内糖萼损伤的参数。
要点
- 透析患者d-HDL和外源性SDMA可剂量依赖性破坏内皮糖萼
- SDMA通过TLR2和MMP-9介导糖萼损伤
- 生物有效HDL可独立预测体内糖萼损伤
核心结论
- d-HDL中的SDMA介导慢性肾脏病内皮糖萼破坏。
研究设计与样本
- 转化性横断面研究,比较健康供者、血液透析患者HDL及外源性SDMA对内皮糖萼的影响。
主要发现
- 健康供者完整HDL维持糖萼,而透析患者HDL及外源性SDMA呈剂量依赖性破坏内皮细胞糖萼。
- SDMA通过TLR2和MMP-9介导糖萼退化。
- 活体显微镜显示外源性SDMA和透析患者d-HDL导致糖萼分解并改变白细胞滚动。
- 生物有效HDL是唯一可独立预测体内糖萼损伤的参数。
临床怎么用
- 生物有效HDL或可作为评估CKD内皮糖萼损伤的潜在指标。
局限性
- 横断面设计无法确定因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Dysfunctional high-density lipoprotein (d-HDL) in chronic kidney disease is known to have a change in composition towards an endothelial-damaging phenotype, amongst others, via the accumulation of symmetric dimethylarginine. The endothelial glycocalyx, a carbohydrate-rich layer lining the endothelial luminal surface, is a first line defense against vascular diseases including atherosclerosis. Here we conducted a translational, cross-sectional study to determine the role of symmetric dimethylarginine in d-HDL as a mediator of glycocalyx damage. Using confocal and atomic force microscopy, intact HDL from healthy donors was found to maintain the glycocalyx while isolated HDL from hemodialysis patients and exogenous symmetric dimethylarginine caused significant damage to the glycocalyx in endothelial cells in vitro in a dose-dependent manner. Symmetric dimethylarginine triggered glycocalyx deterioration via molecular pathways mediated by toll-like-receptor 2 and matrix metalloprotease-9. Corresponding intravital microscopy revealed that exogenous symmetric dimethylarginine and d-HDL from hemodialysis patients caused glycocalyx breakdown, which subsequently contributed to alterations in leukocyte rolling. Biologically effective HDL, which estimates the functionality of HDL, was calculated from circulating HDL-cholesterol and symmetric dimethylarginine, as described in the literature. Biologically effective HDL was the only parameter that could independently predict glycocalyx damage in vivo. Thus, our data suggest that symmetric dimethylarginine in d-HDL mediates glycocalyx breakdown in chronic kidney disease.
引用
- Hesse B, Rovas A, Buscher K, et al. Symmetric dimethylarginine in dysfunctional high-density lipoprotein mediates endothelial glycocalyx breakdown in chronic kidney disease. Kidney Int. 2019. PMID: 32008804. doi:10.1016/j.kint.2019.10.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。